Skip to main content
SpringerLink
Log in

Recognition and Treatment of Idiopathic Pulmonary Fibrosis

  • Disease Management
  • Published:
Drugs Aims and scope Submit manuscript

Summary

The diagnosis of idiopathic pulmonary fibrosis can be made only after exclusion of other entities such as neoplasm, toxic treatments, collagen vascular diseases, occupational exposure or granulomatous diseases, such as sarcoidosis. The repercussions on gas exchanges are the most reliable indications of the severity of the disease, the measure of lung volume or chest x-rays alone often being misleading. Biopsies obtained during transbronchial procedures by thoracoscopies or thoracotomy are of great help, but mainly to rule out other diseases. In many cases, only a high resolution computerised tomography (CT) scan and bronchoalveolar lavage are performed to rule out infection or tumour and to assess the inflammatory state of the disease.

Due to the fact that barely a quarter of patients respond to corticosteroids alone, cytostatics (in particular azathioprine) are often prescribed simultaneously with low dose corticosteroids, either initially or after an unsuccessful trial of corticosteroids. Cyclosporin has been useful for only a limited number of patients. Colchicine has been shown useful in an open trial but its role still needs to be assessed. Anticytokine therapy and the role of substances such as relaxin are still at the experimental stage. Lung transplantation is now a therapeutic option for selected patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Webb WR. High resolution lung computed tomography: normal anatomic and pathologic findings. Radiol Clin North Am 1991; 29: 1051–63

    PubMed  CAS  Google Scholar 

  2. Crystal RG, Bitterman PB, Rennard SI, et al. Interstitial lung diseases of unknown cause: disorders characterized by chronic inflammation of the lower respiratory tract (second of two parts). N Engl J Med 1984; 310: 235–44

    Article  PubMed  CAS  Google Scholar 

  3. Fulmer JD, Roberts WC, Moss ML, et al. Idiopathic pulmonary fibrosis: clinical, histological, radiographic, physiologic, scintigraphic, cytologic, and biochemical aspects. Ann Intern Med 1976; 85: 769–88

    PubMed  Google Scholar 

  4. Orens JB, Kazerooni EA, Martinez FJ, et al. The sensitivity of high-resolution CT in detecting idiopathic pulmonary fibrosis proved by open lung biopsy: prospective study. Chest 1995 July; 108: 109–15

    Article  PubMed  CAS  Google Scholar 

  5. Watters LC, King TE, Schwarz MI, et al. A clinical radiographic and physiologic scoring system for the longitudinal assessment of patients with idiopathic pulmonary fibrosis. Am Rev Respir Dis 1986; 133: 97–103

    PubMed  CAS  Google Scholar 

  6. Wolff, G, Crystal R. Biologic basis of pulmonary fibrosis. In: Crystal R, West J, Weibel E, et al., editors. The lung. New York: Raven Press, 1997: 2509–24

    Google Scholar 

  7. Villard J, Dayer-Pastore F, Hamacher J, et al. GRO alpha and interleukin-8 in Pneumocystis carinii or bacterial pneumonia and adult respiratory distress syndrome. Am J Respir Crit Care Med 1995 Nov; 152: 1549–54

    PubMed  CAS  Google Scholar 

  8. Rochester CL, Elias JA. Cytokines and cytokine networking in the pathogenesis of interstitial and fibrotic lung disorders. Semin Respir Med 1993; 14: 389–416

    Article  Google Scholar 

  9. Behr J, Maier K, Krombach F, et al. Pathogenetic significance of reactive oxygen species in diffuse fibrosing alveolitis. Am Rev Respir Dis 1991; 144: 146–50

    Article  PubMed  CAS  Google Scholar 

  10. Cantin AM, Hubbard RC, Crystal RG. Glutathione deficiency in the epithelial lining fluid of the lower respiratory tract in idiopathic pulmonary fibrosis. Am Rev Respir Dis 1989; 139: 370–2

    Article  PubMed  CAS  Google Scholar 

  11. Fujimoto K, Kubo K, Yamaguchi S, et al. Eosinophil activation in patients with pulmonary fibrosis. Chest 1995; 108: 48–54

    Article  PubMed  CAS  Google Scholar 

  12. Sheppard MN, Harrison NK. New perspectives on basic mechanism in lung disease: lung injury, inflammatory mediators, and fibroblast activation in fibrosing alveolitis. Thorax 1992; 47: 1064–74

    Article  PubMed  CAS  Google Scholar 

  13. McAnulty RJ, Laurent GJ. Pathogenesis of lung fibrosis and potential new therapeutic strategies. Exp Nephrol 1995; 3: 96–107

    PubMed  CAS  Google Scholar 

  14. Kapanci Y, Desmouliere A, Pache JC, et al. Cytoskeletal protein modulation in pulmonary alveolar myofibroblasts during idiopathic pulmonary fibrosis: possible role of transforming growth factor beta and tumor necrosis factor alpha. Am J Respir Crit Care Med 1995 Dec; 152: 2163–9

    PubMed  CAS  Google Scholar 

  15. Broekelmann TJ, Limper AH, Colby TV, et al. Transforming growth factor β1 is present at sites of extracellular matrix gene expression in human pulmonary fibrosis. Proc Natl Acad Sci USA 1991; 88: 6421–46

    Article  Google Scholar 

  16. Wilborn J, Crofford LJ, Burdick MD, et al. Cultured lung fibroblasts isolated from patients with idiopathic pulmonary fibrosis have a diminished capacity to synthesize prostaglandin E2 and to express cyclooxygenase-2. J Clin Invest 1995 Apr 4: 1861–8

    Article  Google Scholar 

  17. Carrington CB, Gaensler EA, Coutu RE, et al. Natural history and treated course of usual and desquamative interstitial pneumonia. N Engl J Med 1978; 298: 801–9

    Article  PubMed  CAS  Google Scholar 

  18. Turner-Warwick MB, Burrows B, Johnson A. Cryptogenic fibrosing alveolitis: response to corticosteroid treatment and its effect on survival. Thorax 1980; 35: 593–9

    Article  PubMed  CAS  Google Scholar 

  19. Watters LC, Schwarz MI, Cherniack RM, et al. Idiopathic pulmonary fibrosis: pretreatment bronchoalveolar lavage cellular constituents and their relationships with lung histopathology and clinical response to therapy. Am Rev Respir Dis 1987; 135: 696–704

    PubMed  CAS  Google Scholar 

  20. Keogh BA, Bernardo J, Hunninghake GW, et al. Effect of intermittent high dose parenteral corticosteroids on the alveolitis of idiopathic pulmonary fibrosis. Am Rev Respir Dis 1983; 127: 18–22

    PubMed  CAS  Google Scholar 

  21. Johnson MA, Wan SK, Snell NJS, et al. Randomised controlled trial comparing prednisolone alone with cyclophosphamide and low dose prednisolone in combination in cryptogenic fibrosing alveolitis. Thorax 1989; 44: 280–8

    Article  PubMed  CAS  Google Scholar 

  22. Hanson D, Winterbauer RH, Kirtland SH, et al. Changes in pulmonary function test results after 1 year of therapy as predictors of survival in patients with idiopathic pulmonary fibrosis. Chest 1995 Aug; 108(2): 305–10

    Article  PubMed  CAS  Google Scholar 

  23. Dayton CS, Schwartz DA, Helmers RA, et al. Outcome of subjects with idiopathic pulmonary fibrosis who fail corticosteroid therapy: implications for further studies. Chest 1993; 103: 69–73

    Article  PubMed  CAS  Google Scholar 

  24. Raghu G, Depaso WJ, Cain K, et al. Azathioprine combined with prednisone in the treatment of idiopathic pulmonary fibrosis: a prospective double-blind, randomized, placebo-controlled clinical trial. Am Rev Respir Dis 1991; 144: 291–6

    Article  PubMed  CAS  Google Scholar 

  25. Peters SG, McDougall JC, Douglas WW, et al. Colchicine in the treatment of pulmonary fibrosis. Chest 1993; 103: 101–4

    Article  PubMed  CAS  Google Scholar 

  26. De Remee RA. New approaches to the treatment of pulmonary fibrosis [editorial; comment]. Eur Respir J 1994; 7: 461–4

    Google Scholar 

  27. Alton EWFW, Johnson M, Turner-Warwick M. Advanced cryptogenic fibrosing alveolitis: preliminary report on treatment with cyclosporin A. Respir Med 1989; 83: 277–9

    Article  PubMed  CAS  Google Scholar 

  28. Moolman JA, Bardin PG, Rossouw DJ, et al. Cyclosporin as a treatment for interstitial lung disease of unknown aetiology. Thorax 1991; 46: 592–5

    Article  PubMed  CAS  Google Scholar 

  29. Sauty A, Rochat Th, Schoch OD, et al. Case study: pulmonary fibrosis with predominant CD8 lymphocytic alveolitis and anti-Jo-1 antibodies. Eur Respir J. In press

  30. Coker RK, Laurent GJ. Anticytokine approaches in pulmonary fibrosis: bringing factors into focus. Thorax 1997; 52: 294–6

    Article  PubMed  CAS  Google Scholar 

  31. Giri SN, Hyde DM, Hollinger MA. Effect of antibody to transforming growth factor-beta on bleomycin induced accumulation of lung collagen in mice. Thorax 1993; 48: 959–66

    Article  PubMed  CAS  Google Scholar 

  32. Taniyama M, Ohbayashi S, Narita M, et al. Pharmacokinetics of an antifibrotic agent, pirfenidone, in haemodialysis patients. Eur J Clin Pharmacol 1997; 52: 77–8

    Article  PubMed  CAS  Google Scholar 

  33. Unemori EN, Pickford LB, Salles AL, et al. Relaxin induces an extracellular matrix-degrading phenotype in human lung fibroblasts in vitro and inhibits lung fibrosis in a murine model in vivo. J Clin Invest 1996 Dec; 98(12): 2739–45

    Article  PubMed  CAS  Google Scholar 

  34. Hunninghake GW, Kalica AR. Approaches to the treatment of pulmonary fibrosis [workshop summary]. Am J Respir Crit Care Med 1995; 151:915–8

    PubMed  CAS  Google Scholar 

  35. Behr J, Maier K, Degenkolb B, et al. Antioxidative and clinical effects of high-dose N-acetylcysteine in fibrosing alveolitis. Am J Respir Crit Care Med 1997; 156: 1897–901

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Pulmonary Division, Cantonal Hospital, 1211, Geneva 14, Switzerland

    Laurent P. Nicod

Authors
  1. Laurent P. Nicod
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Laurent P. Nicod.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Nicod, L.P. Recognition and Treatment of Idiopathic Pulmonary Fibrosis. Drugs 55, 555–562 (1998). https://doi.org/10.2165/00003495-199855040-00006

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-199855040-00006

Keywords

Search

Navigation